Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.75 Average PT from Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been given an average rating of “Moderate Buy” by the six analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $13.75.

VYGR has been the topic of a number of recent research reports. Weiss Ratings reissued a “sell (d)” rating on shares of Voyager Therapeutics in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Wedbush reiterated an “outperform” rating and set a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. Finally, HC Wainwright lowered their price objective on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, November 12th.

Institutional Investors Weigh In On Voyager Therapeutics

Several hedge funds have recently made changes to their positions in the business. Wexford Capital LP purchased a new position in shares of Voyager Therapeutics during the 3rd quarter worth about $42,000. Bank of Montreal Can bought a new position in Voyager Therapeutics during the 2nd quarter worth approximately $36,000. Coldstream Capital Management Inc. bought a new stake in Voyager Therapeutics during the third quarter valued at $55,000. EHP Funds Inc. acquired a new position in Voyager Therapeutics in the third quarter valued at approximately $58,000. Finally, R Squared Ltd acquired a new position in shares of Voyager Therapeutics during the second quarter valued at $48,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Stock Performance

NASDAQ VYGR opened at $3.94 on Wednesday. The firm has a market cap of $219.06 million, a price-to-earnings ratio of -1.82 and a beta of 1.28. The firm has a 50 day simple moving average of $4.08 and a 200-day simple moving average of $4.05. Voyager Therapeutics has a one year low of $2.64 and a one year high of $5.78.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.06. The company had revenue of $11.15 million for the quarter, compared to analysts’ expectations of $7.86 million. Voyager Therapeutics had a negative return on equity of 48.94% and a negative net margin of 404.85%. Equities analysts predict that Voyager Therapeutics will post -0.91 EPS for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.